open access

Vol 69, No 3-4 (2019)
Review paper
Published online: 2019-10-31
Get Citation

New developments in the perioperative treatment of melanomas with locoregional advancement

Piotr Rutkowski1, Wojciech M. Wysocki234, Tomasz Świtaj1, Arkadiusz Jeziorski5
·
Nowotwory. Journal of Oncology 2019;69(3-4):97-102.
Affiliations
  1. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
  2. Faculty of Medicine and Health Studies, A. Frycz-Modrzewski Krakow Academy, Poland
  3. Scientific Office, Maria Skłodowska-Curie Institute – Oncology Center, Warsaw, Poland
  4. General, Oncological and Vascular Surgery Clinic, 5 Military Clinical Hospital in Krakow, Poland
  5. Oncological Surgery Clinic, Medical University in Łódź, Poland

open access

Vol 69, No 3-4 (2019)
Review article
Published online: 2019-10-31

Abstract

Surgical intervention is the treatment of choice for patients with melanomas. However, the prognoses of the patients with melanomas at the IIC–IV stage, even after a complete resection of the lesions, is very diverse and, to a great degree, connected with a high risk of disease recurrence. The positive results of the studies in this area have resulted in systemic adjuvant therapy becoming the standard for patients in this group. New methods of systemic treatment – both the mo­lecularly targeted treatment with BRAF and MEK inhibitors (dabrafenib with trametinib) and anti-PD-1 immunotherapy (nivolumab or pembrolizumab) – are already registered in the United States and the European Union. Also the results of the studies concerning the use of preoperative systemic treatment in patients with loco-regionally advanced melanomas seem to be very promising.

Abstract

Surgical intervention is the treatment of choice for patients with melanomas. However, the prognoses of the patients with melanomas at the IIC–IV stage, even after a complete resection of the lesions, is very diverse and, to a great degree, connected with a high risk of disease recurrence. The positive results of the studies in this area have resulted in systemic adjuvant therapy becoming the standard for patients in this group. New methods of systemic treatment – both the mo­lecularly targeted treatment with BRAF and MEK inhibitors (dabrafenib with trametinib) and anti-PD-1 immunotherapy (nivolumab or pembrolizumab) – are already registered in the United States and the European Union. Also the results of the studies concerning the use of preoperative systemic treatment in patients with loco-regionally advanced melanomas seem to be very promising.

Get Citation

Keywords

melanoma; adjuvant treatment; preoperative treatment; BRAF inhibitors; MEK inhibitors; immunotherapy; anti-PD-1

About this article
Title

New developments in the perioperative treatment of melanomas with locoregional advancement

Journal

Nowotwory. Journal of Oncology

Issue

Vol 69, No 3-4 (2019)

Article type

Review paper

Pages

97-102

Published online

2019-10-31

Page views

465

Article views/downloads

544

DOI

10.5603/NJO.2019.0019

Bibliographic record

Nowotwory. Journal of Oncology 2019;69(3-4):97-102.

Keywords

melanoma
adjuvant treatment
preoperative treatment
BRAF inhibitors
MEK inhibitors
immunotherapy
anti-PD-1

Authors

Piotr Rutkowski
Wojciech M. Wysocki
Tomasz Świtaj
Arkadiusz Jeziorski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl